Similarly, MRX-2843, a dual MerTK/Axl inhibitor, has shown preclinical synergy with checkpoint inhibitors in AML, gliomas, and ovarian cancer by blocking myeloid-driven immune suppression (130). This evidence concerns the gene AXL and ovarian carcinoma.